COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease
Launched by LUZERNER KANTONSSPITAL · Oct 4, 2023
Trial Information
Current as of June 08, 2025
Recruiting
Keywords
ClinConnect Summary
The COMPLEX Registry is a study designed to understand how patients with complex and calcified coronary artery disease (CAD) are treated and what their outcomes are after procedures like angioplasty (PCI) or bypass surgery (CABG). The study will gather information from patients both before and after their treatment to see how different methods and technologies affect their heart health. Researchers will compare the results between those who had PCI and those who had CABG to learn more about the best ways to help patients with challenging heart conditions.
To participate in this study, individuals must be over 18 years old and have chronic, complex, and/or calcified CAD that requires either PCI or CABG. This includes patients with specific types of heart issues, such as heavily calcified arteries or previous stent failures. Participants will need to provide informed consent, indicating that they understand the study and agree to take part. If you or someone you know is dealing with this type of heart disease, joining this study could help improve future treatments for others with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject \>18 years of age
- • Individuals presenting with chronic, complex and/or calcified CAD and requiring PCI or CABG
- * Complex coronary artery disease / lesions must include at least one of the following attributes:
- • Long and/ or heavily calcified coronary lesions
- • In-stent restenosis
- • Chronic total occlusions (CTO)
- • Left main lesions
- • Bifurcation lesions
- • Bypass graft lesions
- • Small vessel disease / coronary microvascular dysfunction (e.g. not amenable to PCI)
- • Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).
- Exclusion Criteria:
- • The presence of any one of the following exclusion criteria will lead to exclusion of the patient.
- • Patient is \<18 years of age
- • Patient unwilling or unable to provide informed consent
- • Patients with no complex and calcified CAD
About Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) is a leading academic hospital located in Lucerne, Switzerland, dedicated to providing high-quality healthcare and advancing medical research. As a prominent clinical trial sponsor, LUKS is committed to fostering innovation in medical treatments and therapies through rigorous clinical studies. The institution emphasizes collaboration with multidisciplinary teams of healthcare professionals, researchers, and academic partners to ensure that its trials adhere to the highest ethical standards and regulatory requirements. With a focus on improving patient outcomes, LUKS leverages its state-of-the-art facilities and expertise to contribute significantly to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lucerne, , Switzerland
Patients applied
Trial Officials
Florim Cuculi, MD
Principal Investigator
Luzerner Kantonsspital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported